Background: A diet high in trans-fatty acids (TFA) induces insulin resistance in rodent models and primates. However, previous epidemiological studies on the association between TFAs, based primarily on self-reported intake from the diet, and diabetes in humans have yielded conflicting results. Herein we examined the associations of objectively measured plasma TFA concentrations with diabetes in a large population-based study among US adults. Methods: We included 3801 participants aged ≥20 years from the National Health and Nutrition Examination Survey 1999-2000 and 2009-10. Four major TFAs, namely palmitelaidic acid (C16:1 n-7t), elaidic acid (C18:1 n-9t), vaccenic acid (C18:1 n-7t), and linolelaidic acid (C18:2 n-6t, 9t), were measured in fasting plasma using gas chromatography-mass spectrometry. Diabetes was defined by self-reported physician diagnosis, plasma fasting glucose ≥126 mg/ dL, or HbA1c ≥6.5%. Results: After adjustment for other major risk factors, the odds ratios (95% confidence intervals) of diabetes comparing the highest with lowest quintile of plasma TFAs was 2.19 (1.27-3.79) for total TFAs (P trend = 0.01), 2.34 (1.48-3.72) for elaidic acid (P trend = 0.0004), 1.33 (0.82-2.15) for linolelaidic acid (P trend = 0.18), 1.58 (0.97-2.58) for palmitelaidic acid (P trend = 0.02), and 1.64 (0.95-2.84) for vaccenic acid (P trend = 0.08). In addition, total TFAs,
Introduction
Trans-fatty acids (TFAs) are fatty acids with at least one non-conjugated double bond in the trans configuration. 1 In the past, TFAs, mainly from the partial hydrogenation of vegetable oils, were widely used in the food industry, and although their use is declining, TFAs are still found in some processed foods today. 2 Humans could also ingest TFAs in a small amount from dairy products and meats. 3 Since 2005, the Dietary Guidelines for Americans have recommended reducing TFA consumption to as low as possible. 4 Under concerns of the adverse health effects of TFAs, the US Food and Drug Administration (FDA) published a final rule, effective 1 January 2006, requiring that nutrition labels for all conventional foods and supplements must indicate the TFA content. 5 In 2015, the FDA released a final determination that partially hydrogenated oils are not "generally recognized as safe" for use in food, and requested the food companies to eliminate them from food in 3 years. 6 These measures have led to significantly reduced plasma TFA levels in the US population. 6, 7 Trans-fatty acids have attracted critical attention as a potential modifiable risk factor for diabetes. 8 Diabetes is a worldwide public health issue due to its severe complications and increasing prevalence. 9 Previous studies about associations between TFAs and diabetes have yielded conflicting results. 10, 11 For example, Papantoniou et al. found that TFA intake was not associated with diabetes, 10 whereas Salmeron et al. found a positive and significant association with diabetes. 11 These inconsistencies may be due, in part, to the use of dietary questionnaires, which are subject to measurement errors caused by recall bias and inaccurate estimation. Therefore, studies using TFA biomarkers that provide more objective and reliable measure of TFA status are needed. So far, only a few studies have examined the associations between circulating TFA isomers and diabetes, yielding inconsistent findings. [12] [13] [14] [15] [16] Moreover, biological samples in those studies were collected before 2006, so associations between TFA biomarkers and diabetes after the sharp drop in TFA exposure after 2006 are not known. 7, 17 In addition, those studies were conducted in middle-aged or older adults. No information about young adults has been reported.
In the present study, we examined the associations of plasma concentrations of total TFAs and individual TFA isomers with diabetes and diabetic biomarkers in a wide age range using data from nationally representative surveys.
Methods

Study population
The National Health and Nutrition Examination Survey (NHANES) is a nationally representative survey of the non-institutionalized US population. It is administered by the National Center for Health Statistics at the Centers for Disease Control and Prevention (CDC) and collects data on demographics, socioeconomic status, lifestyle, diet, and medical conditions, as well as specimens for laboratory tests, which are publicly released in 2-year cycles. Detailed descriptions of NHANES are available elsewhere. 18 NHANES has been approved by the National Center for Health Statistics Ethics Review Board. Written informed consent was obtained from all participants to take part in NHANES.
For this analysis, we used data from NHANES 1999-2000 and 2009-10, because only these two cycles included available data on plasma TFA concentrations. 7 Of the 20 502 participants in NHANES 1999-2000 and 2009-10, plasma TFAs were measured in a fasting morning sample from 4029 adults aged ≥20 years. Individuals with missing information on total blood lipids (n = 47) were excluded because TFA was adjusted for total blood lipids as recommended. 19 Pregnant women (n = 114) and individuals who had cardiovascular disease prior to the diagnosis of diabetes (n = 38) were also excluded from the analysis. Moreover, given that body mass index (BMI) is an important confounder of the association between TFA and diabetes 20 and that only 0.8% of individuals (n = 29) had missing data on BMI, individuals without BMI data were excluded from the analysis. Thus, the final sample consisted of 3801 participants (48% men, mean [AE SD] age 50.1 AE 17.9 years; 52% women, mean [AE SD] age 50.0 AE 17.8 years; see Fig. S1 , available as Supplementary Material to this paper).
Exposure assessment
Four major TFA isomers, namely palmitelaidic acid (C16:1 n-7t), elaidic acid (C18:1 n-9t), vaccenic acid (C18:1 n-7t), and linolelaidic acid (C18:2 n-6t, 9t), were measured in fasting plasma samples using gas chromatography-mass spectrometry at the Division of Laboratory Sciences, National Center for Environmental Health, CDC. 21 These TFA isomers are the most abundant circulating TFA isomers and provide a reasonable representation of TFAs in the blood. 17 Total TFAs were calculated as the sum of these four TFA isomers.
The instrument details have been described elsewhere. 21 The lower limits of detection (LLOD) were 0.07 μmol/L for palmitelaidic acid, 0.28 μmol/L for elaidic acid, 0.43 μmol/L for vaccenic acid, and 0.02 μmol/L for linolelaidic acid. The detection limits were constant for all the analytes in the data set. All the measured TFA levels were at or above the LLOD. All TFA isomers were expressed as relative values (μmol/g lipids) by dividing their concentrations by total blood lipids, as recommended. 19 
Outcome ascertainment
Diabetes was defined based on self-reported physician diagnosis, a plasma fasting glucose level of ≥126 mg/dL, or HbA1c ≥6.5% or more. 22 Trained interviewers collected information on self-reported diabetes diagnosis using a computer-assisted personal interview system. HbA1c levels, plasma fasting glucose, and fasting insulin were measured from blood specimens collected during the examination and then analyzed later by an accredited laboratory using a standardized protocol. 23, 24 Insulin resistance index was evaluated based on the updated homeostasis model of assessment (HOMA2-IR). 25 
Potential confounders
Information on age, gender, race/ethnicity, family income, education, smoking status, medical conditions, and family history of diabetes was collected during the NHANES in-person home interviews. Race/ethnicity was categorized as non-Hispanic white, non-Hispanic black, Mexican American, and other race/ethnicity (other race and other Hispanic). Education was grouped as less than high school, high school, and higher than high school (including some college or associates (AA) degree, college graduate or higher). Family income-to-poverty ratios, which were calculated by dividing family income by the poverty guidelines specific to family size, as well as the appropriate year and state (see https://aspe.hhs.gov/poverty-guidelines, accessed 27 February 2018), were categorized as ≤1.30, 1.31-3.50, and >3.50. 26 Individuals who smoked fewer than 100 cigarettes in their lifetime were defined as never smokers; those who had smoked more than 100 cigarettes but did not smoke at the time of the survey were considered former smokers; and those who had smoked more than 100 cigarettes and smoked cigarettes at the time of survey were current smokers. 27 Validity of self-reported smoking in NHANES was confirmed by an objectively measured biomarker in a previous study, with 96% of self-reported smokers having serum cotinine levels ≥3 ng/mL and 91% of selfreported non-smokers (either never smokers or former smokers) having serum cotinine levels <3 ng/mL. 28 Dietary information was collected through 24-h dietary recall interviews. Total energy intake was calculated using the USDA Automated Multiple-Pass Method. 29 Alcohol intake was categorized as 0, 0.1-27.9, or ≥28 g/ day for men, and 0, 0.1-13.9, or ≥14 g/day for women. Physical activity was classified into three groups according to standards appropriate for each cycle, 30, 31 because there were some changes in physical activity questionnaires between NHANES 1999-2000 and 2009-10, as follows: (i) below, <600 metabolic equivalents (MET) min/week or 150 min/week moderate-intensity exercise; (ii) meet, 600-1200 MET min/week or 150-300 min/ week moderate-intensity exercise; or (iii) exceed, >1200 MET min/week or 300 min/week moderate-intensity exercise. Weight and height were measured by trained health technicians. Body mass index was calculated as weight in kilograms divided by height in meters squared and classified into three groups: <25, 25-29.9, and ≥30 kg/m 2 . The 2010 healthy eating index (HEI-2010) score was calculated to represent diet quality, with a higher score indicating a better diet. 32 
Statistical analysis
A complex, multistage probability sampling design was used in NHANES to represent the civilian noninstitutionalized US population. Weighted estimates were used to adjust for the differential probability of selection and non-response. Because TFA was measured on a fasting morning sample, the fasting sample weights were used in the analyses. The Taylor series linearization method was used for variance estimation to account for stratification and clustering, following the NHANES Analytic Guidelines. 26 Plasma TFA concentrations were log transformed prior to analysis because of skewed distributions. We used analysis of variance to compare differences in total calorie intake, alcohol intake, and HEI score among quintiles of plasma TFA concentrations. We used Chisquared tests to compare the distribution of categorical variables, such as sex, race/ethnicity, and education levels, among quintiles of plasma TFA concentrations. Pearson correlations with sample weights were used to calculate correlation coefficients among concentrations of each TFA isomer. Logistic regression was used to estimate the odds ratios (ORs) of diabetes according to quintiles of plasma TFA concentrations. Among individuals without diabetes, linear regression was used to estimate the association between TFAs and biomarkers of glucose metabolism, including fasting glucose, fasting insulin, HOMA2-IR, and HbA1c. We adjusted for a number of potential confounders in our analysis, including age, gender, race/ethnicity, and survey cycle (Model 1), with additional adjustment for education, family income-to-poverty ratios, smoking status, alcohol intake, total energy intake, physical activity, family history of diabetes, and HEI-2010 (Model 2), and BMI (Model 3) because BMI may be a confounder or mediator of the associations between plasma TFAs and diabetes. 20, 33 Categorical covariates included a subgroup for missing data, if necessary. To test linear trends across quintiles of TFA concentrations, we assigned the median for each quintile and fitted the log-transformed median as a continuous variable in models. We also repeated the analyses in each survey cycle (1999) (2000) separately.
To evaluate effect modification, we conducted stratified analyses according to age (20-49, ≥50 years), gender (men, women), and race/ethnicity (non-Hispanic white, other racial/ethnic groups). P-values for heterogeneity were derived from the multiplicative interaction term coefficients (exposure variable × effect modifier variable) added to the main effects multivariable model.
To detect the robustness of our findings, we conducted a sensitivity analysis by excluding individuals who reported only insulin use, a rough indicator of type 1 diabetes. 34 All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). Statistical significance was set at the 0.05 level. All P-values are twosided.
Results
The median plasma concentration for total TFAs was 8.17 μmol/g lipids (interquartile range [IQR] 5.64-12.41), compared with 3.08 μmol/g lipids (IQR 2.00-4.97) for elaidic acid, 0.63 μmol/g lipids (IQR 0.43-0.94), for linolelaidic acid, 0.77 μmol/g lipids (IQR 0.58-1.07) for palmitelaidic acid, and 3.96 μmol/g lipids (IQR 2.70-6.06) for vaccenic acid. Higher plasma concentrations of total TFAs were found among non-Hispanic white, those with a lower education level, lower physical activity, or higher BMI, and those with family history of diabetes ( Table 1) . Characteristics of the participants according to each TFA isomer are given in Tables S1-S4. The four isomers were highly correlated with each other; correlation coefficients ranged from 0.79 to 0.93 (P < 0.001 for all). Plasma concentrations of total TFAs and each TFA isomer according to population characteristics are given in Table S5 .
Association between TFAs and diabetes
We found a significant association between plasma total TFAs and diabetes. After adjustment for demographic, socioeconomic, lifestyle, dietary factors, and a family history of diabetes, the OR of diabetes for total TFA levels, comparing the highest quintile with the lowest, was 2.19 (95% confidence interval [CI] 1.27-3.79; P trend = 0.01; Table 2 ). The association was modestly attenuated, but remained significant, after additional adjustment for BMI (OR 1.83, 95% CI 1.04-3.21; P trend = 0.056). We also examined the association between each TFA isomer and the presence of diabetes. The multivariable-adjusted ORs of diabetes for the different TFA isomers, comparing the highest quintile with the lowest, were 2.34 (95% CI 1.48-3.72; P trend = 0.0004) for elaidic acid, 1.33 (95% CI 0.82-2.15; P trend = 0.18) for linolelaidic acid, 1.58 (95% CI 0.97-2.58; P trend = 0.02) for palmitelaidic acid and 1.64 (95% CI 0.95-2.84; P trend = 0.08) for vaccenic acid (Table 2 ). When we simultaneously included the four TFA isomers in the same multivariable model, significant associations were only found between elaidic acid and diabetes (OR 3.27, 95% CI 1.64-6.51; P trend = 0.001). The observed associations did not differ significantly by age, gender, or race/ ethnicity (Tables S6-S8) .
To determine whether the associations between TFAs and diabetes changed after the reduction in TFA levels, we examined the associations between TFAs and diabetes in each survey cycle. In NHANES 1999-2000, we found significant associations between total plasma TFAs and diabetes (P trend = 0.02). The multivariable adjusted OR for diabetes, comparing the highest with lowest quintile, was 2.54 (95% CI, 1.07-6.03; Table 3 ). In NHANES 2009-10, the association was attenuated, with a corresponding OR of 1.59 (95% CI 0.94-2.68; P trend = 0.06; Table 4 ). For individual TFA isomers, only elaidic acid was significantly associated with 
Association between TFAs and biomarkers of glucose metabolism
We found significant associations between total plasma TFAs and biomarkers of glucose metabolism in adults without diabetes. In the multivariable-adjusted model, plasma total TFA concentration was significantly associated with fasting glucose (P trend = 0.007), fasting insulin (P trend = < 0.001), HOMA2-IR (P trend = < 0.001), and HbA1c (P trend = 0.003; Table 5 ). Analyses of individual TFA isomers showed a significant association of biomarkers of glucose metabolism with elaidic acid, vaccenic acid, and palmitelaidic acid, but not linolelaidic acid (Table 5) . 
Discussion
To our knowledge, the present study is the first to comprehensively examine the association between plasma concentrations of the four major TFA isomers and diabetes. In this nationally representative population, higher plasma concentrations of total TFAs, in particular elaidic acid, were positively and significantly associated with diabetes in US adults, even after adjustment for other risk factors.
In adults without diabetes, total TFAs, elaidic acid, palmitelaidic acid, and vaccenic acid were positively associated with biomarkers of altered glucose metabolism.
The association between total TFA concentrations, which were objectively measured in plasma samples, and diabetes was consistent with several previous studies linking dietary TFA intake based on dietary questionnaires to diabetes. Higher dietary TFA intake has been associated with diabetes, 11 insulin sensitivity, 35 and systemic inflammation. 36 Animal studies have found that a high-TFA diet induces significant insulin resistance in mice 37 and causes weight gain and impaired insulin sensitivity in monkeys. 38 in vivo and in vitro studies have found that TFAs can inhibit the Model 2 was adjusted for all factors in Model 1 plus education (less than high school, high school, higher than high school), family income (family income to poverty ratio ≤1.30, 1.31-3.50, >3.50, or missing), cigarette smoking (never, past, current smoker), physical activity (below, meet, exceed), alcohol intake (men: 0, 0.1-27.9, or ≥28 g/day; women: 0, 0.1-13.9, or ≥14 g/day), family history of diabetes (yes, no), total energy intake (quintiles), and 2010 healthy eating index (HEI-2010) score 32 (quintiles). OR, odds ratio; CI, confidence interval; TFA, trans-fatty acid.
expression of peroxisome proliferator-activated receptor γ, which plays an important role in glucose metabolism. 39 Other underlying mechanisms may include the effects on liver X receptor and sterol regulatory element-binding protein-1. 1 Effects of specific TFA isomers on the development of diabetes remain to be determined. Previous studies have yielded inconsistent findings, which may be due, in part, to the different ways to estimate specific TFA exposure, either based on dietary questionnaires 11 or measurements in blood samples. 15 Studies examining the associations of selected individual blood TFA isomers with diabetes are sparse, and the TFA isomers measured in previous studies varied. Wang et al. used data from the Cardiovascular Health Study and found that phospholipid trans-16:1 n-9 and trans-18:1 were positively associated with diabetes among older adults. 13 Mozaffarian et al. found that transpalmitelaidic acid was associated with a lower risk of diabetes in US adults, 14, 15 whereas a Finnish study Model 1 was adjusted for age (years), gender (men, women), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, and other race/ethnicity). Model 2 was adjusted for all factors in Model 1 plus education (less than high school, high school, higher than high school), family income (family income to poverty ratio ≤1.30, 1.31-3.50, >3.50, or missing), cigarette smoking (never, past, current smoker), physical activity (below, meet, exceed), alcohol intake (men: 0, 0.1-27.9, or ≥28 g/day; women: 0, 0.1-13.9, or ≥14 g/day), family history of diabetes (yes, no), total energy intake (quintiles), and 2010 healthy eating index (HEI-2010) score 32 (quintiles). OR, odds ratio; CI, confidence interval; TFA, trans-fatty acid.
showed that neither trans-palmitelaidic acid nor elaidic acid were significantly associated with diabetes. 12 In a previous study among Chinese adults examining the associations between erythrocyte fatty acids and multiple cardiometabolic traits, erythrocyte trans-18:1 fatty acid, but not trans-18:2 fatty acid, was associated with a lower risk of type 2 diabetes. 16, 40 As suggested previously, 41 the sources of various trans-18:1 isomers may be quite different: trans-18:1 Δ4-Δ10 primarily come from industrial products, whereas trans-18:1 Δ11 comes from ruminants. In the present study, we found that trans-18:1 isomers Δ11 (i.e. 18:1 n-7t) showed a weaker association with diabetes than trans-18:1 isomers Δ9 (i.e. 18:1 n-9t). This is in line with existing evidence indicating less adverse effects of ruminant TFAs than industrial TFAs on cardiometabolic health. 42 Other factors, including study design, population characteristics, and confounders, may have contributed to the inconsistent findings on associations of TFAs with diabetes. Importantly, the time frame in which these studies were Model 1 was adjusted for age (years), gender (men, women), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, and other race/ethnicity). Model 2 was adjusted for all factors in Model 1 plus education (less than high school, high school, higher than high school), family income (family income to poverty ratio ≤1.30, 1.31-3.50, >3.50, or missing), cigarette smoking (never, past, current smoker), physical activity (below, meet, exceed), alcohol intake (men: 0, 0.1-27.9, or ≥28 g/day; women: 0, 0.1-13.9, or ≥14 g/day), family history of diabetes (yes, no), total energy intake (quintiles), and 2010 healthy eating index (HEI-2010) score 32 (quintiles). OR, odds ratio; CI, confidence interval; TFA, trans-fatty acid.
conducted may be an important factor. In the US, FDA policies and guidelines were published in 2006 to call for a limited intake of TFAs, which did cause a sharp decrease in human exposure to TFAs. 7 The blood samples in all the aforementioned US studies were collected before 2006. [13] [14] [15] Circulating TFA levels in studies in China 16 and Finland 12 were lower than those in the US, and the range is relatively narrower. The relatively smaller range of TFA levels of these previous studies compared with the present analysis may limit the ability to detect a difference in the risk of diabetes. In addition, dairy products, the main sources of palmitelaidic acid and vaccenic acid, also contain other bioactive nutrients (i.e. vitamin D, calcium, magnesium, casein, and whey protein) in different amounts. Because these nutrients may contribute to a lower risk of diabetes, 43 they could mask the potential adverse effects of TFAs on diabetes. 43 Clearly, further investigation is warranted to clarify the association between specific TFA isomers and diabetes.
Consistent with findings between plasma TFA concentrations and diabetes, we observed positive and significant associations between some plasma TFAs and fasting glucose, fasting insulin, HOMA2-IR, and HbA1c in adults without diabetes. Similar findings were observed in the study of Itcho et al., in which serum elaidic acid concentrations were associated with insulin resistance. 44 Angelieri et al. also reported detrimental effects of TFA intake on insulin sensitivity. 35 A major strength of the present study is a broader range of TFA levels compared with those in previous studies. The geometric mean of total TFAs in NHANES 1999-2000 and NHANES 2009-10 was 81.4 and 37.8 μmol/L, respectively, representing a 54% decrease in plasma TFA concentrations between these two cycles. 7, 26 Taking advantage of data from these two survey cycles, which provided a larger range of TFA levels, could have increased the ability to detect associations between TFAs and diabetes.
1 This is supported by our analysis in specific survey cycles. We did not find significant associations between palmitelaidic acid and diabetes in NHANES 1999-2000 or NHANES 2009-10, which is consistent with previous studies. 12 However, the association between palmitelaidic acid and diabetes turned out to be significant when these two cycles were merged together. .50, or missing), cigarette smoking (never, past, current), physical activity (below, meet, exceed), alcohol intake (men: 0, 0.1-27.9, or ≥28 g/day; women: 0, 0.1-13.9, or ≥14 g/day), family history of diabetes (yes, no), total energy intake (quintiles), and 2010 healthy eating index (HEI-2010) score 32 (quintiles).
TFA, trans-fatty acid.
The present study has other strengths as well. First, to our knowledge, the present study is the first to comprehensively examine the association between plasma concentrations of TFAs and diabetes in a nationally representative study in the US, which allows for better generalizability of the findings to a broader population. Second, plasma TFA isomers were measured directly, which is more reliable and not subject to recall bias, as seen in previous questionnaire-based studies. 45 Third, the present study provides new data in the general population by including all adults aged ≥20 years, as opposed to only older adults, as studied previously. 12, 13 Finally, biomarkers of glucose metabolism, such as fasting glucose and HbA1c, were measured in a large sample size to support our findings on diabetes. As expected, we observed consistent results for the associations of plasma TFAs with diabetes and biomarkers of glucose metabolism.
We acknowledge that the present study also has some limitations. First, due to the cross-sectional nature of NHANES, we cannot draw a causal inference from the observed associations. Second, NHANES did not provide sufficient data to distinguish between type 1 and type 2 diabetes. However, the results were robust when we excluded individuals who reported only insulin use, a rough indicator of type 1 diabetes. 34 Third, NHANES did not measure total plasma TFA directly. Instead, total TFA was calculated using the four major TFA isomers that are the most abundant in blood samples. The summing of these four major TFA isomers has been used in previous studies to estimate total TFA concentration in the US population. 7 Fourth, although many potential confounders were adjusted for, we cannot rule out the possibility of residual confounding by unknown factors.
In conclusion, in the present nationally representative study, we found significant associations of plasma concentrations of total TFAs, in particular elaidic acid, with diabetes and biomarkers of glucose metabolism in US adults. The results of the present study support the US federal regulation reducing TFA intake in the general population.
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